ReviewMuscle & nerve2020
Management challenges for chronic dysimmune neuropathies during the COVID-19 pandemic.
Review in Muscle & nerve, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Physical Activity in Patients with Neuromuscular Disease Three Years after COVID-19, a Longitudinal Survey: The After-Effects of the Quarantine and the Benefits of a Return to a Healthier Life-Style.Journal of clinical medicine · 2024Article
- A Scoping Review of Barriers and Facilitators Affecting the Lives of People With Disabilities During COVID-19.Frontiers in rehabilitation sciences · 2021Article
- Impact of COVID-19 pandemic in the activity of a Therapeutic Apheresis unit in Italy.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2020Article
- Facing acute neuromuscular diseases during COVID-19 pandemic: focus on Guillain-Barré syndrome.Acta neurologica Belgica · 2020Review
- Neurological immunotherapy in the era of COVID-19 - looking for consensus in the literature.Nature reviews. Neurology · 2020Review
- Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review.JAMA neurology · 2020Review
- Amyotrophic lateral sclerosis care and research in the United States during the COVID-19 pandemic: Challenges and opportunities.Muscle & nerve · 2020Article
- Management challenges for chronic dysimmune neuropathies during the COVID-19 pandemic.Muscle & nerve · 2020Review
- COVID-19 and management of neuroimmunological disorders.Nature reviews. Neurology · 2020Review
- Neuromuscular Diseases Care in the Era of COVID-19.Frontiers in neurology · 2020Article
- Neurological manifestations of severe acute respiratory syndrome coronavirus 2-a controversy 'gone viral'.Brain communications · 2020Review
- Radiological profile of patients undergoing Chest X-ray and computed tomography scans during COVID-19 outbreak.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 4 countries.
Funding
Abstract
Since March 2020, the COVID-19 pandemic has led to the need to re-think the delivery of services to patients with chronic dysimmune neuropathies. Telephone/video consultations have become widespread but have compounded concerns about objective evaluation. Therapeutic decisions need, more than ever before, to be considered in the best interests of both patients, and society, while not denying function-preserving/restoring treatment. Immunoglobulin therapy and plasma exchange, for those treated outside of the home, expose patients to the hazards of hospital or outpatient infusion centers. Steroid therapy initiation and continuation pose increased infectious risk. Immunosuppressant therapy similarly becomes highly problematic, with the risks of treatment continuation enhanced by uncertainties regarding duration of the pandemic. The required processes necessitate considerable time and effort especially as resources and staff are re-deployed to face the pandemic, but are essential for protecting this group of patients and as an integral part of wider public health actions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.